myelodysplastic syndromes (MDS) | Page 14 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia

Author(s): 
Natalie Ertz-Archambault, MD; Heidi Kosiorek, MS; Gretchen E. Taylor, MD; et al Katalin Kelemen, MD, PhD; Amylou Dueck, PhD; Janna Castro, BS; Robert Marino, MS; Susanne Gauthier, RN; Laura Finn, MD; Lisa Z. Sproat, MD; Jeanne Palmer, MD; Ruben A. Mesa
Primary Author: 
Natalie Ertz-Archambault, MD
Journal Title: 
JAMA Oncol
Original Publication Date: 
Feb 2017

Importance  Therapy-related myeloid neoplasms are a potentially life-threatening consequence of treatment for autoimmune disease (AID) and an emerging clinical phenomenon.

Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes

Author(s): 
Garcia-Manero G, Montalban-Bravo G, Berdeja JG, Abaza Y, Jabbour E, Essell J, Lyons RM, Ravandi F, Maris M, Heller B, DeZern AE, Babu S, Wright D, Anz B, Boccia R, Komrokji RS, Kuriakose P, Reeves J, Sekeres MA, Kantarjian HM, Ghalie R, Roboz GJ
Primary Author: 
Garcia-Manero G
Journal Title: 
Cancer
Original Publication Date: 
Jan 2017

BACKGROUND:

Bone Marrow Diseases: 

Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?

Author(s): 
Stahl M, Zeidan AM
Primary Author: 
Stahl M
Journal Title: 
Cancer
Original Publication Date: 
Jan 2017

No abstract available.

Bone Marrow Diseases: 

Prophylactic RhCE and Kell antigen matching: impact on alloimmunization in transfusion-dependent patients with myelodysplastic syndromes

Author(s): 
Lin Y, Saskin A, Wells RA, Lenis M, Mamedov A, Callum J, Buckstein R
Primary Author: 
Lin Y
Journal Title: 
Vox Sang
Original Publication Date: 
Jan 2017

BACKGROUND AND OBJECTIVES:

Bone Marrow Diseases: 

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs. de novo myelodysplastic syndromes: A report on behalf of the MDS clinical research consortium

Author(s): 
Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R
Primary Author: 
Zeidan AM
Journal Title: 
Leukemia
Original Publication Date: 
Jan 2017

While therapy-related (t)-MDS has worse outcomes than de novo MDS (d-MDS), some t-MDS patients have an indolent course. Most MDS prognostic models excluded t-MDS patients during development.

Bone Marrow Diseases: 

Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes

Author(s): 
Chou WC, Yeh SP, Hsiao LT, Lin SF, Chen YC, Chen TY, Laille E, Galettis A, Dong Q, Songer S, Beach CL
Primary Author: 
Chou WC
Journal Title: 
Asia Pac J Clin Oncol
Original Publication Date: 
Jan 2017

AIM:

Bone Marrow Diseases: 

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Author(s): 
Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA
Primary Author: 
Greenberg PL
Journal Title: 
J Natl Compr Canc Netw
Original Publication Date: 
Jan 2017

The

Bone Marrow Diseases: